Sidharta Krisna, Muhammad
Unknown Affiliation

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

Trends in Artificial Intelligence Research in Urology, Anesthesiology, Cardiology, and Otolaryngology: A Bibliometric Analysis (2019-2024) Sidharta Krisna, Muhammad; Alfi Reza, Muhammad; Ghiffary, Muamar; Satir Sayati, Muhammad; Awaluddin, Muhammad
International Journal of Health and Pharmaceutical (IJHP) Vol. 5 No. 1 (2025): February 2025 (Indonesia - Turkey - Malaysia - Australia - Iran)
Publisher : CV. Inara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51601/ijhp.v5i1.403

Abstract

Background: The application of Artificial Intelligence (AI) in medicine is rapidly evolving, particularly in urology, anesthesiology, cardiology, and otolaryngology (ENT). AI is utilized in image-based diagnosis, patient monitoring, as well as the optimization of therapy and robotic surgery. However, research trends in AI within these fields have not yet been comprehensively mapped. Methods: This study employs bibliometric analysis to evaluate publication trends in AI across these four medical fields from 2019 to 2024. Data were collected from Google Scholar, PubMed, and Scopus, then analyzed using VOSviewer and R-Bibliometrix to identify the number of publications, keyword trends, institutional collaboration networks, and the most highly cited articles. Results: The number of AI-related publications in medicine has increased from 50 articles in 2019 to 130 articles in 2024. The United States, China, and the United Kingdom have the highest number of publications. Research trends indicate that deep learning and machine learning dominate, with broad applications in disease diagnostics and medical imaging. Cluster analysis reveals four main domains: anesthesiology (120 publications), cardiology (105 publications), urology (98 publications), and ENT (80 publications). Conclusion: AI has become an essential component in the advancement of modern medicine. With the increasing number of studies and multidisciplinary collaborations, AI is projected to continue expanding in data-driven diagnosis and therapy. However, challenges in clinical validation, regulation, and AI ethics must be addressed to ensure its safe and effective use.
Mapping the Future: A Content Analysis of the Evolution of Gene Therapy in Urological Cancer Sidharta Krisna, Muhammad; Alfi Reza, Muhammad; Aksanda Putra, Bobby; Muslim Siregar, Bukhari; Alif Adhani, Muhammad
International Journal of Health and Pharmaceutical (IJHP) Vol. 5 No. 1 (2025): February 2025 (Indonesia - Turkey - Malaysia - Australia - Iran)
Publisher : CV. Inara

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51601/ijhp.v5i1.404

Abstract

Background: Gene Therapy Has Emerged As A Promising Approach In The Treatment Of Urological Cancers, Including Prostate, Kidney, And Bladder Cancers. Over The Past Decade, Significant Advancements Have Been Made In Gene Editing Technologies Such As Crispr-Cas9, Rna-Based Therapies, And Viral Vector Systems. These Innovations Offer Precise Targeting Of Oncogenes And Tumor Suppressor Genes, Potentially Improving Treatment Efficacy And Reducing Adverse Effects Compared To Conventional Therapies. Methods: A Systematic Content Analysis Was Conducted On Peer-Reviewed Literature And Clinical Trial Reports From 2015 To 2025. Databases Such As Pubmed, Sciencedirect, And Scopus Were Used To Extract Relevant Studies. Inclusion Criteria Encompassed Original Research Articles, Systematic Reviews, And Clinical Trials Focused On Gene Therapy Applications In Prostate, Kidney, And Bladder Cancer. Studies Exclusively Conducted On In Vitro Or Animal Models Without Clinical Relevance Were Excluded. Results: Crispr-Cas9 Has Demonstrated High Precision In Gene Editing, Particularly In Prostate Cancer, Where Targeting Androgen Receptor-Related Genes Has Enhanced Hormone Therapy Sensitivity. Rna Therapy, Especially Using Sirna Targeting Vegf And Hif-1α, Has Shown Promise In Kidney Cancer Treatment By Inhibiting Angiogenesis. Viral Vectors Remain A Primary Method For Gene Delivery In Bladder Cancer, Although Immune Responses Pose A Significant Challenge. Clinical Trials Indicate That Gene Therapy Combined With Immunotherapy, Particularly Checkpoint Inhibitors Like Pembrolizumab, Enhances Treatment Efficacy. However, Regulatory Barriers, High Costs (Estimated At Over $500,000 Per Patient), And Safety Concerns Regarding Off-Target Effects Remain Major Obstacles To Widespread Clinical Implementation. Conclusion: Despite These Challenges, Gene Therapy Holds Great Potential For Revolutionizing Urological Cancer Treatment. Future Research Should Focus On Optimizing Gene Delivery Systems, Reducing Off-Target Risks, And Developing Cost-Effective Production Methods. Personalized Gene Therapy Approaches, Leveraging Advancements In Genomic Sequencing, Are Expected To Further Enhance Treatment Precision. With Continued Innovation And Regulatory Advancements, Gene Therapy Is Anticipated To Become An Integral Part Of Standard Urological Cancer Care In The Coming Decade.